More than 30% of all clinical trials run by Veristat are for rare diseases. We’re passionate about helping clients accelerate their therapies through the clinical development process.
With 300 million living with a rare disease, we applaud the work of the organizers of Rare Disease Day, whose mission is for equitable access to diagnosis, treatment, and opportunity. More than 30% of all clinical trials run by Veristat are for rare diseases. We’re passionate about helping clients accelerate their therapies through the clinical development process. Read More
Blog: Flexibility is the Key to Data Acquisition for Rare Disease Trials
The complexities are high when designing a data acquisition strategy for smaller patient populations. We’ve come up with some special considerations for building a database for a rare disease trial— with flexibility at the core.
Case study: Complex Trial for a Rare Pediatric Gene Therapy
A clinical-stage biotechnology start-up asked Veristat to run a new European trial of their complex gene therapy and rescue three ongoing studies challenged by quality concerns. Our cell and gene therapy team delivered by going the extra mile.
Infographic: Benefits of Implementing a Central Site Model
Implementing a central site model may be useful for rare disease programs when patients are located across the globe. Our guide walks through how to implement this model which benefits patients and sponsors.
Presentation: Gene Therapy for Rare Disorders 2021
February 24, 2021, 11:30 am EST Mark your calendar for an informative presentation by Rachel Smith, Project Director, on ‘Creative Solutions for Complex Clinical Development Pathways | Case studies from Clinical Trials’
The FDA has enhanced its rare disease patient website to help patients and families better navigate the FDA’s organization and its offices supporting the rare disease space. Learn more
